FDA Compares New Products' DTC Ads To Competitor Campaigns
This article was originally published in The Pink Sheet Daily
If two products have similar risks and claims, their advertisements should include similar presentations, FDA DTC review group leader Moncavage suggests. Companies can learn how to design ads by assessing the letters FDA sends to violators, she says.
You may also be interested in...
The agency pledges further review of its guidance on direct-to-consumer advertising. Broadcast ads for drugs and enforcement actions against repeat offenders could see more attention.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states